Spotlight on Research

Dr. Thomas Waddell, a senior scientist and thoracic surgeon (lung transplantation doctor) at the University Health Network in Toronto, is looking to tackle this challenge. Dr. Waddell is receiving funding from Cystic Fibrosis Canada from 2022-2025 for his research study, The use of immune-modified pluripotent safe cells in cell replacement therapy for Cystic Fibrosis.

Dr. Yossef Av-Gay is a professor at the University of British Columbia and has been recently funded by Cystic Fibrosis Canada through the 2021 Grants & Awards Competition for his study, Hit to lead: Novel agents against Mycobacterium abscessus.

Dr. Emile Levy, a professor in the Department of Nutrition at the University of Montreal and Scientific Director of the Gastroenterology, Hepatology and Nutrition Unit at Le Centre hospitalier universitaire Sainte-Justine, recently received funding from Cystic Fibrosis Canada for his study, "Therapeutic efficacy of polyphenols in experimental cystic fibrosis: their role in intestinal inflammation, oxidative stress and microbiota dysbiosis.” Cystic Fibrosis Canada awarded this funding as part of our 2021 Grants & Awards Competition and are looking forward to the results of the study.

Dr. Jin-A Lee, from SickKids was recently awarded a two year research fellowship grant from Cystic Fibrosis Canada for her research study, A mutation-independent role of TMEM16A in airway cystic fibrosis therapy.  

Research fellowships are awarded to applicants to our Grants & Awards Competition who have completed a PhD or MD degree within the last five years and are doing an independent research project in an academic lab. Dr. Lee hopes to identify the role of TMEM16A, which is a calcium-chloride channel, as well as determine the effects of upregulating TMEM16A in helping epithelial function. The ultimate goal is to find a way to target TMEM16A to help compensate for defective CFTR function in CF patients.  

Dr. Lee’s research relates to the community health priority: Cure CF with gene or stem cell therapies. It and also focuses on individuals who will not benefit from modulators.

In late 2021, we were able to co-fund with Michael Smith Health Research BC a three-year research trainee award for a researcher working to develop a non-invasive diagnostic for lung infections in CF. Dr. Shekooh Behroozian, a post-doctoral fellow at the University of British Columbia working in the laboratory of Dr. Jane Hill, received this award for her study, Development of a non-invasive diagnostic to detect bacterial pulmonary infections in patients with cystic fibrosis. This work aligns with our community health priorities: Improve airway infection detection and?treatment? and Predict and prevent pulmonary?exacerbations?.

Dr. Cara Haney is a professor at the University of British Columbia and has recently been funded with an Early Career Investigator award through Cystic Fibrosis Canada’s 2021 Grants & Awards competition for her research study, Pseudomonas aeruginosa environmental sensing to establish chronic infection. Early Career Investigators are researchers who have recently opened an independent research laboratory at a university or hospital research institute. CF Canada has placed a priority on funding strong researchers who are early in their careers to help build and maintain a robust CF research community in Canada, now and into the future, with the skills we will need for the next generation of breakthroughs in CF.  

Dr. Amanda Morris, a research fellow at the Hospital for Sick Children, has recently been awarded a research fellowship from Cystic Fibrosis Canada for her study, In vivo exploration of Pseudomonas aeruginosa and Staphylococcus aureus Interactions within Sputum of Cystic Fibrosis patients with Pulmonary Exacerbations.  

Dr. Christine Bear is an award-winning researcher at the Hospital for Sick Children (SickKids) in Toronto, who recently received funding from Cystic Fibrosis Canada to pursue her research study, Multi-site collaboration to validate use of patient-derived nasal cultures for expanding access to CFTR modulators. Dr. Bear hopes to find a way that Trikafta can be used for CF patients with mutations other than the most common F508del mutation. Through the use of nasal cells, there could be evidence that Trikafta can improve lung health for those who have been denied access due to their rare mutations.

Cystic Fibrosis Canada is proudly able to support this research thanks to a generous grant for basic science research from the Sarah Gordon Sutherland Memorial Fund. Our sincere thanks to the Gordon family for making this work possible.

Dr. Robert Hancock is the Killam Professor of Microbiology and Immunology and a Canada Research Chair at the University of British Columbia. He has published more than 700 scientific papers and has received several high-profile awards and honours in recognition of his work, including being appointed as an Officer of the Order of Canada in 2001. Dr. Hancock’s research focuses on understanding and overcoming antibiotic resistance and developing new treatments for difficult-to-treat infections, like Pseudomonas aeruginosa.

What I enjoy the most about my work is the process of discovery - the design of experiments and the development of experimental techniques that allow us to advance our understanding of CF.